Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Firebrick Pharma Limited ( (AU:FRE) ).
Firebrick Pharma has secured an initial order for 216 units of its newly launched Nasodine Throat Spray from Fiji and South Pacific licensee Makans Ltd, marking the product’s entry into the Fiji market shortly after its rollout in Singapore. The shipment, supplied by Australian manufacturer Probiotec, will support promotional activities to doctors and pharmacists starting in February, with Makans positioning the throat spray as a complementary extension to Nasodine Nasal Spray for inactivating viruses, including Covid, and killing bacteria linked to respiratory infections—an early step in building the Nasodine brand as a household name across Fiji and the wider South Pacific region.
The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.
More about Firebrick Pharma Limited
Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its primary products include Nasodine Nasal Spray, a 0.5% PVP-I antiviral and antibacterial nasal spray already introduced in the United States, Singapore, and Fiji & South Pacific, and the follow-on Nasodine Throat Spray, with the company targeting additional approvals in markets such as the Philippines.
Average Trading Volume: 103,759
Technical Sentiment Signal: Hold
Current Market Cap: A$15.85M
Learn more about FRE stock on TipRanks’ Stock Analysis page.